Approved BTKis, given as continuous therapy for a prolonged time, and fixed-duration venetoclax (BCL-2 inhibitor) in combination with an anti-CD20 monoclonal antibody (obinutuzumab or rituximab) are the mainstay treatments for front-line and relapsed/refractory chronic lymphocytic leukemia.3 This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.